REGN (Regeneron Pharmaceuticals) GF Value Rank : 8 (As of Apr. 17, 2025)

View and export this data going back to 1991. Start your Free Trial

What is Regeneron Pharmaceuticals GF Value Rank?

Regeneron Pharmaceuticals has the GF Value Rank of 8.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Regeneron Pharmaceuticals's GF Value Rank

For the Biotechnology subindustry, Regeneron Pharmaceuticals's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's GF Value Rank falls into.

Save Embed

;

Save Embed

;

Regeneron Pharmaceuticals GF Value Rank Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

REGN:Mexico 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Executives

Marion Mccourt	officer: SVP Commercial	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Arthur F Ryan	director	CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
Christopher R. Fenimore	officer: VP, Controller	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Andrew J Murphy	officer: EVP Research	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Neil Stahl	officer: SVP, Preclinical Development	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph J Larosa	officer: SVP Gen Counsel & Secretary	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Michael S Brown	director
Leonard S Schleifer	director, officer: President & CEO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
George Yancopoulos	director, officer: President and CSO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
George L Sing	director	LANCET CAPITAL, 45 ROCKEFELLER PLAZA STE 2008, NEW YORK NY 10111
Van Plew Daniel P	officer: EVP & General Mgr Industrial O	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein	director	DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390
Huda Y Zoghbi	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591